ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VXRT Vaxart Inc

0.76
-0.0823 (-9.77%)
Apr 19 2024 - Closed
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Vaxart Inc VXRT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0823 -9.77% 0.76 19:57:30
Open Price Low Price High Price Close Price Prev Close
0.82 0.7503 0.8568 0.7556 0.8423
more quote information »

Recent News

Date Time Source Heading
3/27/202408:00GLOBEVaxart to Present at World Vaccine Congress Washington 2024..
3/20/202408:00GLOBEVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing..
3/14/202416:01GLOBEVaxart Provides Business Update and Reports Full Year 2023..
3/14/202407:41IHMARKETNEWSU.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil..
3/07/202408:00GLOBEVaxart to Host Full Year 2023 Business Update and Financial..
3/06/202409:23EDGAR2Form 8-K - Current report
3/06/202408:00GLOBEVaxart, Inc. Appoints Steven Lo as President, Chief..
2/29/202416:30EDGAR2Form 8-K - Current report
2/15/202416:10EDGAR2Form 8-K - Current report
2/13/202417:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/05/202408:00GLOBEVaxart Announces Publication in Vaccines of Non-Human..
2/02/202416:49EDGAR2Form 8-K/A - Current report: [Amend]
1/19/202417:14EDGAR2Form 8-K - Current report
1/19/202416:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
1/19/202408:30GLOBEVaxart Receives $9.27 Million BARDA Project NextGen Award to..
1/16/202417:18EDGAR2Form 8-K - Current report
1/16/202409:25GLOBEVaxart Announces $10.0 Million Registered Direct Offering..
1/16/202409:22GLOBEVaxart, Inc. Announces Management Change
1/16/202409:19EDGAR2Form 8-K - Current report
12/21/202308:00GLOBEVaxart Announces Last Subject Dosed in Phase 1 Trial of Its..
11/02/202316:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/02/202316:11EDGAR2Form 8-K - Current report
11/02/202316:01GLOBEVaxart Provides Business Update and Reports Third Quarter..
11/02/202308:00GLOBEVaxart Doses First Subject in Phase 1 Trial of Its Norovirus..
10/26/202308:00GLOBEVaxart to Host Third Quarter 2023 Business Update and..
10/23/202317:09EDGAR2Form 8-K/A - Current report: [Amend]
10/23/202317:01EDGAR2Form 8-K - Current report
10/11/202308:00GLOBEVaxart to Present at World Vaccine Congress Europe 2023 on..
9/21/202308:00GLOBEVaxart to Participate in Fireside Chat at 2023 Cantor Global..
9/06/202316:43EDGAR2Form 8-K - Current report
9/06/202316:05GLOBEVaxart Announces Topline Data from the Phase 2 Challenge..
8/03/202316:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/03/202316:20EDGAR2Form 8-K - Current report
8/03/202316:01GLOBEVaxart Provides Business Update and Reports Second Quarter..
8/01/202321:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/01/202321:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/01/202321:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/01/202321:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/01/202320:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/27/202308:00GLOBEVaxart to Host Second Quarter 2023 Business Update and..
7/26/202316:20EDGAR2Form 8-K - Current report
7/10/202316:12EDGAR2Form 8-K - Current report
7/06/202308:00GLOBEVaxart Announces Positive Preliminary Topline Data from..
6/28/202316:22EDGAR2Form 8-K - Current report
6/26/202316:45GLOBEVaxart Stockholders Approve All Four Proposals in the 2023..
6/21/202316:30GLOBEVaxart Encourages All Stockholders of Record as of April 28,..
6/07/202309:16GLOBEVaxart, Inc. Announces Pricing of $15,000,000 Public..
6/06/202316:01GLOBEVaxart, Inc. Announces Proposed Public Offering of Common..
6/06/202308:00GLOBEVaxart Announces Last Subject Dosed in Phase 2 Trial of its..
5/31/202308:00GLOBEVaxart Launches New Investor Communication Program, First..

Your Recent History

Delayed Upgrade Clock